156 related articles for article (PubMed ID: 11027509)
1. Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry.
Li BQ; Fu T; Dongyan Y; Mikovits JA; Ruscetti FW; Wang JM
Biochem Biophys Res Commun; 2000 Sep; 276(2):534-8. PubMed ID: 11027509
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV infection by baicalin--a flavonoid compound purified from Chinese herbal medicine.
Li BQ; Fu T; Yan YD; Baylor NW; Ruscetti FW; Kung HF
Cell Mol Biol Res; 1993; 39(2):119-24. PubMed ID: 7693133
[TBL] [Abstract][Full Text] [Related]
3. Inefficient formation of a complex among CXCR4, CD4 and gp120 in U937 clones resistant to X4 gp120-gp41-mediated fusion.
Xiao X; Norwood D; Feng YR; Moriuchi M; Jones-Trower A; Stantchev TS; Moriuchi H; Broder CC; Dimitrov DS
Exp Mol Pathol; 2000 Jun; 68(3):139-46. PubMed ID: 10816382
[TBL] [Abstract][Full Text] [Related]
4. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Blanco J; Barretina J; Clotet B; Esté JA
J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
[TBL] [Abstract][Full Text] [Related]
5. Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes.
Barrero-Villar M; Cabrero JR; Gordón-Alonso M; Barroso-González J; Alvarez-Losada S; Muñoz-Fernández MA; Sánchez-Madrid F; Valenzuela-Fernández A
J Cell Sci; 2009 Jan; 122(Pt 1):103-13. PubMed ID: 19066282
[TBL] [Abstract][Full Text] [Related]
6. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
[TBL] [Abstract][Full Text] [Related]
7. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
8. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4.
Boutet A; Salim H; Taoufik Y; Lledo PM; Vincent JD; Delfraissy JF; Tardieu M
Glia; 2001 May; 34(3):165-77. PubMed ID: 11329179
[TBL] [Abstract][Full Text] [Related]
9. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion.
Ablan S; Rawat SS; Viard M; Wang JM; Puri A; Blumenthal R
Virol J; 2006 Dec; 3():104. PubMed ID: 17187670
[TBL] [Abstract][Full Text] [Related]
10. HIV envelope proteins differentially utilize CXCR4 and CCR5 coreceptors for induction of apoptosis.
Yao Q; Compans RW; Chen C
Virology; 2001 Jun; 285(1):128-37. PubMed ID: 11414813
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
[TBL] [Abstract][Full Text] [Related]
12. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
13. Specific CD4 down-modulating compounds with potent anti-HIV activity.
Vermeire K; Schols D
J Leukoc Biol; 2003 Nov; 74(5):667-75. PubMed ID: 12960237
[TBL] [Abstract][Full Text] [Related]
14. Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells.
Fantini J; Hammache D; Delézay O; Piéroni G; Tamalet C; Yahi N
Virology; 1998 Jul; 246(2):211-20. PubMed ID: 9657940
[TBL] [Abstract][Full Text] [Related]
15. Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection.
Kamiyama H; Yoshii H; Tanaka Y; Sato H; Yamamoto N; Kubo Y
Virology; 2009 Mar; 386(1):23-31. PubMed ID: 19178925
[TBL] [Abstract][Full Text] [Related]
16. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
Azevedo-Pereira JM; Santos-Costa Q
Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
[TBL] [Abstract][Full Text] [Related]
17. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
19. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
20. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.
Mariner JM; McMahon JB; O'Keefe BR; Nagashima K; Boyd MR
Biochem Biophys Res Commun; 1998 Jul; 248(3):841-5. PubMed ID: 9704015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
